3-芳基-5-噻吩基二氢吡唑磺酰胺衍生物的合成及其抗炎活性研究

二氢吡唑是一类含有多种生物活性的五元氮杂环化合物,广泛存在于各种活性天然产物结构中。本文由4-氟苯乙酮和N-甲基哌嗪经取代反应后,再与2-噻吩甲醛发生羟醛缩合生成哌嗪取代噻吩查尔酮(2)。化合物2与水合肼环化得到中间体化合物3,最后经磺酰氯衍生化,合成得到8个未见报道的3-芳基-5-噻吩基二氢吡唑磺胺衍生物(4a～4h),其结构均经IR、~1H NMR和~(13)C NMR确证。采用小鼠巨噬细胞Raw264. 7模型初步测试了衍生物的抗炎活性,结果表明,化合物4a、4e和4h具有潜在的体外抗炎活性,特别是化合物4a抑制NO生成的IC_(50)值为12. 64μmol/L,与阳性对照药地塞米松活性相当。     

1,2,7,9-四取代去氢骆驼蓬碱衍生物的合成及体外抗肿瘤活性

为了寻找高效低毒的抗肿瘤候选化合物, 以去氢骆驼蓬碱为原料, 对β-咔啉环的2-,7-和9-位3个结构位点进行了结构改造, 合成了11个去氢骆驼蓬碱衍生物, 化合物的结构经核磁共振、 红外光谱、 质谱及元素分析确证. 采用四甲基偶氮唑盐(MTT)法初步测试了目标化合物体外抗肿瘤(Bel-7402, 786-0, BGC-823, A375, 769-P和MCF7)活性, 结果表明化合物4a, 4b, 8a和8b具有显著的体外抗肿瘤活性.     

3-芳基-5-噻吩基二氢吡唑磺酰胺衍生物的合成及其抗炎活性研究

二氢吡唑是一类含有多种生物活性的五元氮杂环化合物,广泛存在于各种活性天然产物结构中。本文由4-氟苯乙酮和N-甲基哌嗪经取代反应后,再与2-噻吩甲醛发生羟醛缩合生成哌嗪取代噻吩查尔酮(2)。化合物2与水合肼环化得到中间体化合物3,最后经磺酰氯衍生化,合成得到8个未见报道的3-芳基-5-噻吩基二氢吡唑磺胺衍生物(4a～4h),其结构均经IR、~1H NMR和~(13)C NMR确证。采用小鼠巨噬细胞Raw264. 7模型初步测试了衍生物的抗炎活性,结果表明,化合物4a、4e和4h具有潜在的体外抗炎活性,特别是化合物4a抑制NO生成的IC_(50)值为12. 64μmol/L,与阳性对照药地塞米松活性相当。     

胱胺衍生物的合成及抗非小细胞肺癌活性研究

为寻求活性强的非小细胞肺癌(NSCLC)药物,设计合成了一系列胱胺衍生物4a～4g,并对其抗NSCLC活性进行了初步探讨.以胱胺为起始原料,经过加成、还原反应得到了目标化合物,采用CCK-8法对其抗NSCLC细胞增殖活性进行了测试.目标化合物4a～4g结构经ESI-MS、1 H-NMR、13 C-NMR谱确证.活性结果...     

1-(2-羟基苯甲酰基)-3-甲基-4-取代苯腙基-吡唑啉酮及其中间体的合成、表征及抑菌活性

依据生物活性叠加原理,将邻羟苯基、吡唑啉酮、苯腙基团进行合理组合,构建并合成了2-取代苯腙基-3-(2-羟基苯甲酰腙基)-丁酸乙酯(3a～3f)和1-(2-羟基苯甲酰基)-3-甲基-4-取代苯腙基-吡唑啉酮(4a～4f)两类、共计12种化合物,其中8种化合物未见报道,12种化合物的抑菌活性均未见报道.以芳胺为原料,经重氮化、与乙酰乙酸乙酯反应,与水杨酰肼缩合制得3a～3f,3a～3f经分子内关环制得4a～4f,化合物的结构经IR,1HNMR,元素分析等证实.生物活性测试表明,质量浓度为0.01%时,化合物3b,3c对大肠杆菌的抑菌率高达100%,具有很强的抑菌活性;化合物3a～3f对白色念珠菌、金黄色葡萄球菌的抑菌率均达70%以上,具有较强的抑菌活性;化合物4a～4f对白色念珠菌、大肠杆菌的抑菌率均接近或达到100%,具有很强的抑菌活性,对金黄色葡萄球菌的抑菌率均达78%以上,具有较强抑菌活性;与3a～3f相比,形成吡唑啉酮环后的化合物4a～4f的抗菌活性更高.     

Synthesis and biological activities of some homopiperazine quaternary ammonium

将蜂王酸经醋酐酯化后与1-甲基高哌嗪发生酰化后再季铵化,合成了8个未见文献报道的高哌嗪类季铵盐4a～4h,所有化合物的结构经IR,1H NMR,13C NMR和MS分析确认.考察了这些化合物与乙酰胆碱酯酶(AchE)、丁酰胆碱酯酶(BuchE)、金黄色葡萄球菌的抑制作用,结果表明:化合物4对AchE和BuchE具有较好的抑制活性,其中4c对AchE的抑制效果最好,其IC50 =2.56 μmol/L;4g对BuchE的抑制效果最好,IC50 =6.62 μmol/L;化合物4e,4h在浓度为0.25g/L时对金黄色葡萄球菌(Staphylococcus aureus)的抑菌效果较好.     

作为FABP4/5抑制剂喹啉类化合物的设计合成与生物活性研究（英文）

以罗氏公司报道的FABP4/5双靶标抑制剂RO6806051和FABP4抑制剂XU17为先导化合物,根据RO6806051/FABP5复合物和XU17/FABP4复合物晶体结构,通过骨架融合策略设计并合成了20个以喹啉为母核的结构新颖FABP4/5双靶标小分子抑制剂,其结构经核磁共振氢谱(¹H NMR)、核磁共振碳谱(¹³C NMR)和高分辨质谱(HRMS)确证.采用8-苯胺基萘-8-磺酸(1,8-ANS)底物探针置换法对所合成的目标化合物进行了活性测试,活性结果显示,2-(2-(6-氯-4-(2-氯苯基)喹啉-2-基]苯基)乙酸(11a)对FABP4/5表现出较强的抑制活性,其在25μmol/L浓度下对FABP4抑制率为88%,IC₅₀为4.50μmol/L;对FABP5抑制率为73%,IC₅₀为3.9μmol/L.     

新型苯丙氨酸三肽衍生物的合成及其抗乙肝病毒活性

以具有抗HBV活性的苯丙氨酸二肽化合物马蹄金素(MTS)为先导化合物,设计并合成了23个新型的苯丙氨酸三肽衍生物（4a~4h, 5, 6a, 6b和8a~8k）,其结构经¹H NMR, ¹³C NMR和MS(ESI)表征。采用HepG2 2.2.15细胞为乙肝病毒载体,评价了目标化合物的抗HBV活性。结果表明：化合物5（IC₅₀=2.98 μM）、 6b（IC₅₀=0.62 μM）和8k（IC₅₀=5.07 μM）对HBV DNA复制的抑制活性优于MTS（IC₅₀=11.16 μM）。     

嘧啶并嘧啶酮类化合物作为L3MBTL1选择性络合剂的设计与合成

用嘧啶并嘧啶酮替换Lethal 3 malignant brain tumor 1(L3MBTL1)小分子络合剂UNC669分子中的芳香部分,合成了一系列嘧啶并嘧啶酮类化合物.采用同质邻近发光放大法(AlphaScreen^®)测试了其活性,得到IC₅₀值为1.21 μmol/L的化合物8a;通过对其5位基团进行改造,最终获得了3个选择性L3MBTL1络合剂8g, 8o与8p,它们仅对L3MBTL1有活性,对其同源蛋白L3MBTL3在内的其它甲基化识别蛋白则无活性.     

(8R,8aS)-及(8R,8aR)-8-羟基-5-吲哚里西啶酮的不对称合成:两个有用的羟基吲哚里西啶合成砌块

以3-苄氧基哌啶-2,6-二酮衍生物20为起始原料,分别合成了两类新的合成砌块(8R,8aS)-及(8R,8aR)-8-羟基-5-吲哚里西啶酮19a/19b和15a/15b.19a/19b的合成是基于反式非对映立体选择性还原烷基化反应(dr=93:7),接着经4步转化而成;而化合物15a/15b的制备则以双烯29的RCM反应为关键步骤,再经顺式立体选择性催化氢化(dr=91:9)反应完成.此外,还原化合物15a得到了(8R,8aR)-8-羟基-5-吲哚里西啶18.     

Design and Synthesis of a Series of Pyrido[2,3-d]pyrimidine Derivatives as CCR4 Antagonists

A series of pyrido[2,3-d]pyrimidine derivatives were designed and synthesized based on known CC chemokine receptor 4 (CCR4) antagonists. The activities of all the newly synthesized compounds were evaluated using a chemotaxis inhibition assay. Compound 6b was proven to be a potent CCR4 antagonist that can block cell chemotaxis induced by macrophage-derived chemokine (MDC), thymus and activation regulated chemokine (TARC), and CKLF1, the natural ligands of CCR4. In addition, compound 6b is more effective than budesonide in the murine rhinitis model. The intravenous injection LD₅₀ of compound 6b is 175 mg/kg and the oral LD₅₀ is greater than 2,000 mg/kg.     

Synthesis and anti-integrase evaluation of novel calix[4]arene derivatives containing the triazolyl 1,3-diketo moiety

A series of novel calix[4]arene derivatives incorporating two triazolyl 1 3-diketo subunits in alternate positions at the lower rim were synthesized and screened for HⅣ integrase inhibition activity.The chemical structures of these compounds were confirmed by means of1H NMR 13C NMR,and ESI-MS.Preliminary bioassays indicated that calix[4]arene derivatives proved to be more active than p-tertbutylcalix[4]arene derivatives.In particular,compound 4g presented the most potent integrase strand transfer inhibitory activity with an IC50value of 6.1 mmol/L.     

四甲基吡嗪衍生物合成及其5-HT3受体拮抗活性的筛选

恶性肿瘤常用的内科治疗方法为放射治疗和化学治疗,这两种治疗方法均会造成严重的恶心和呕吐等胃肠道副反应．早期的抗呕吐药物不仅其止吐效果差,还伴有严重的锥体外系副反应．自从20世纪70年代末发现5-HT3受体与呕吐机制有关以来引,5-HT3受体及其拮抗剂的研究极为活跃,目前上市的药物有Ondansetron,Granisetron,Tropisetron和Azasertron等,还有许多药物正处于临床研究阶段。     

Design,Synthesis and Herbicidal Activity of Novel Sulfonylureas Containing Tetrahydrophthalimide Substructure

To develop novel sulfonylurea herbicides, a series of chlorsulfuron derivatives was designed and synthesized through introducing tetrahydrophthalimide substructure taken from protoporphyrinogen IX oxidase(PPO) inhibitors onto the critical 5-position of the classical benzene ring. The structures of title compounds were confirmed by infrared spectroscopy, ultraviolet spectroscopy, ¹H and ¹³C NMR spectrometry, mass spectrometry and elemental analysis. In addition, the crystal structure of compound II-5 was further determined by X-ray diffraction analysis. Bioassay results showed that individual compounds exhibited good herbicidal activities, especially compound II-8, which displayed 100% inhibition rate against Echinochloa crusgalli at 150 g/ha(1 ha=10⁴ m²) with the method of foliage spray in the pot experiment.     

Discovery of ErbB/HDAC inhibitors by combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib,BMS-690514, neratinib,and TAK-285

By combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib, BMS-690514, neratinib, and TAK-285 with 1,2,3-triazole as linker, eight novel 6-substituted-4- aminoquinazolin derivatives were synthesized and characterized by ¹H NMR, ¹³C NMR, and high resolution mass spectrometry. Their inhibitory activities against five enzymes (VEGFR2, HER2, EGFR, HDAC1, and HDAC6) and five cancer cell lines (A549, BT-474, A431, SK-BR-3, and NCI-H1975) were evaluated. The bioassay results show that the introduction of triazole linked vorinostat-like segment dramatically changed the selectivity profiles of newly synthetic compounds relative to vandetanib, BMS- 690514, neratinib, and TAK-285. Among them, compound 6b exerted outstanding enzymatic and cellular activities through its simultaneous and synergistic inhibitions on multiple pathways, which might have the great potential to confer the better benefits than single-targeted inhibitors in cancer therapy.     

Design,Ultrasonic-assisted Synthesis and Evaluation In vitro Antimicrobial Activity of Bis-isoxazole Derivatives Bearing Chloro-pyridinyl Group

An ultrasonic-assisted synthesis of bis-isoxazole derivatives was developed. Eight 3-(6-chloropyridin-3-yl)-5-{[(3-aryli-soxazol-5-yl)methoxy]methyl}isoxazoles were synthesized by 1,3-dipolar cycloaddition reaction between substituted isoxazolyl alkyne compounds and 6-chloro-N-hydroxynicotinimidoyl chloride. The structures of the synthesized compounds were confirmed by HRMS, FTIR, ¹H and ¹³C NMR spectroscopy. Wherein, the antifungal and antibacterial activities of target compounds were tested. The synthesized compounds 6a and 6h exhibited better antifungal activity in comparison with the standard drug itraconazole. The minimum inhibitory concentrations(MICs) of both compound 6a and compound 6h were both 4 μg/mL against Candida albicans ATCC 10231.     

芳香寡聚磺酸酯桥联大环化合物的合成和紫外光谱

以芳香二磺酰氯和芳香二酚为原料,三乙胺作缚酸剂,二氯甲烷作溶剂,采取一步成环法合成了一系列新型的、芳环单元不同的芳香寡聚磺酸酯桥联大环化合物。 合成产物的结构用IR、¹H NMR、¹³C NMR和MALDI-TOF等技术手段进行了确认。 并对合成方法、紫外光谱和变温核磁结构研究进行了有价值的探讨。 化合物3~5的DMF溶液的最大紫外吸收峰在266 nm处,化合物6在267 nm处,摩尔吸光系数分别是4.65×10⁴、5.61×10⁴、5.09×10⁴和9.98×10⁴ L/(mol·cm);检出限分别是2.15×10^-7、1.78×10^-7、1.96×10^-7和1.00×10^-7 mol/L。 变温核磁数据证明,苯环上连有支链有利于固定构象,可以通过这种方法合成结构固定的杯芳烃。     

Synthesis and insecticidal evaluation of tetrahydroimidazo[1,2-a]pyridin-5(1H)-one derivatives

A series of novel tetrahydroimidazo[1,2-a]pyridine-5(1H)-one derivatives containing a electronegative pharmacophore(=CNO₂) were synthesized via practical aza-ene reaction and characterized by ¹H NMR, ¹³C NMR, ¹⁹F NMR and HRMS. Preliminary bioassays showed that some of the target compounds exhibited good insecticidal activity against brown planthopper(Nilaparvata lugens) and cowpea aphids(Aphis craccivora) at 500 mg L^-1. Among them, compound 11h was active against brown planthopper at 100 mg L^-1. The insecticidal activities varied significantly depending on the types and patterns of the substituents, which provided guidance for further investigation on structure modifications.     

Synthesis and thermal properties of novel calix[4]arene derivatives containing 1,2,3-triazole moiety via K2CO3-catalyzed 1,3-dipolar cycloaddition reaction

Two calix[4]arene derivatives containing 1,2,3-triazole moiety were synthesized via K2CO3-catalyzed1,3-dipolar cycloaddition reaction between calix[4]arene-based azide and active methylene compounds in good yields.The structures of the two compounds synthesized herein were fully confirmed by 1HNMR,,（13）C NMR,and MS（ESI）.The thermal analysis showed that the mass losses of the synthesized compounds 4 and 5 containing 1,2,3-triazole groups are similar to each other.     

Synthesis and Biological Evaluation of Amino Alcohol Containing 1,3,4-Oxadiazole

A series of amino alcohol derivatives containing 1,3,4-oxadiazole moieties was synthesized with 7-bromo-2-tetralone as starting materials, 2,2-dimethyl-1,3-oxazolidine as intermediates and Strecker reaction and cyclization with POCl₃ as key steps. The structures of the key intermediate and target compounds were confirmed by ¹H NMR, ¹³C NMR and HRMS. Some compounds have resulted in the generation of highly potent sphingosine 1-phosphate receptor type 1(S1P₁) agonists.